CNS-3 status remains an independent adverse prognosis factor in children with acute lymphoblastic leukemia (ALL) treated without cranial irradiation: Results of EORTC Children Leukemia Group study 58951 - 12/06/21
, S. Suciu c, 1, B. De Moerloose d, A. Ferster e, F. Mazingue f, G. Plat g, K. Yakouben h, A. Uyttebroeck i, C. Paillard j, V. Costa k, P. Simon l, C. Pluchart m, M. Poirée n, O. Minckes o, F. Millot p, C. Freycon q, P. Maes r, C. Hoyoux s, H. Cavé t, u, P. Rohrlich n, Y. Bertrand v, Y. Benoit dfor the
Children's Leukemia Group of the European Organisation for Research Treatment of Cancer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 3 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Aim |
To evaluate the prognostic significance of initial central nervous system (CNS) involvement of children with acute lymphoblastic leukemia (ALL) enrolled in the EORTC 58951 trial.
Patients and methods |
From 1998 to 2008, 1930 ALL patients were included in the randomized EORTC 58951 trial. Overall treatment intensity was adjusted according to known prognostic factors including the level of minimal residual disease after induction treatment. CNS-directed therapy comprised four to 11 courses of i.v. methotrexate (5g/m2), and 10 to 19 intrathecal chemotherapy injections, depending on risk group and CNS status. Cranial irradiation was omitted for all patients.
Results |
The overall 8-year event-free survival (EFS) and overall survival (OS) rates were 81.3% and 88.1%, respectively. In the CNS-1, TPL+, CNS-2, and CNS-3 groups, the 8-year EFS rates were 82.1%, 77.1%, 78.3%, and 57.4%, respectively. Multivariable analysis indicated that initial CNS-3 status, but not CNS-2 or TLP+, was an independent adverse predictor of outcome. The 8-year incidence of isolated CNS relapse was 1.7% and of isolated or combined CNS relapse it was 3.7%. NCI high-risk group, male sex, CNS-2 and CNS-3 status were independent predictors for a higher incidence of any CNS relapse.
Conclusions |
CNS-3 status remains associated with poor prognosis and requires intensification of both systemic and CNS-directed therapy.
This trial was registered at NCT00003728.
Le texte complet de cet article est disponible en PDF.Keywords : Children, Acute lymphoblastic leukemia, Central nervous system
Plan
Vol 28 - N° 5
P. 411-416 - juillet 2021 Retour au numéro
Article précédent
- COVID-19 in children at Strasbourg University Hospital: A retrospective study of the first 2 months of the epidemic
- O. Lavaine, J. Spizzo, C. Arbitre, J. Muller, P. Kuhn, V. Laugel, D. Tchomakov
- Dermatological opinions are imperative in ambulatory and acute care settings for pediatric skin disorders – HL-SkinPed
- Mathilde Moiny-Fouquet, Claire Guillaume, Noémie Berlengi, Lucie Lapp, Claire Watelet, Anne Borsa-Dorion, Yohann Bernard, Cédric Baumann, Amandine Luc, Cyril Schweitzer, Bruno Leheup, Anne-Claire Bursztejn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?